Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children
Chad A. Knoderer Pharm.D.,
Julie A. Everett Pharm.D.,
William F. Buss Pharm.D.,
Corresponding Author
Chad A. Knoderer Pharm.D.
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Room 1016, 702 Barnhill Drive, Indianapolis, IN 46202; e-mail: [email protected].Search for more papers by this authorJulie A. Everett Pharm.D.
School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana
Search for more papers by this authorWilliam F. Buss Pharm.D.
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana
Search for more papers by this authorChad A. Knoderer Pharm.D.,
Julie A. Everett Pharm.D.,
William F. Buss Pharm.D.,
Corresponding Author
Chad A. Knoderer Pharm.D.
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Room 1016, 702 Barnhill Drive, Indianapolis, IN 46202; e-mail: [email protected].Search for more papers by this authorJulie A. Everett Pharm.D.
School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana
Search for more papers by this authorWilliam F. Buss Pharm.D.
Department of Pharmacy Services, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana
Search for more papers by this authorAbstract
Aminoglycoside antibiotics are first-line treatment for many infectious diseases in the pediatric population and are effective in adults. The traditional dosing interval in children is every 8–12 hours. Studies in adults reported equivalent efficacy and equal or less toxicity with once-daily regimens. Despite many studies in the adult population, this approach has yet to become standard practice in most pediatric hospitals. Reasons for lack of acceptance of this strategy in children include rapid aminoglycoside clearance, unknown duration of postantibiotic effect, safety concerns, and limited clinical and efficacy data.
References
- 1 Bailey T.C., Little J.R., Littenberg B., et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786–95.
- 2 Barza M., Ioannidis J.P., Cappelleri J.C., et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338–45.
- 3 Freeman C.D., Nicolau D.P., Belliveau P.P., et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677–86.
- 4 Hatala R., Dinh T.T., Cook D.J.. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810–15.
- 5 Hollender L.F., Bahnini J., De Manzini N., et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989; 23: 773–83.
- 6 Marik P.E., Lipman J., Kobilski S., et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991; 28: 753–64.
- 7 Munckhof W.J., Grayson M.L., Turnidge J.D.. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645–63.
- 8 Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered in 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5.
- 9 Nordstrom L., Ringberg H., Cronberg S., et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990; 25: 159–73.
- 10 Prins J.M., Buller H.R., Kuijper E.J., et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9.
- 11 International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93.
- 12 Sturm A.W.. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159(5): 931–7.
- 13 Rozdzinski E., Kern W.V., Moritz T., et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585–98.
- 14 Chuck S.K., Raber S.R., Rodvold K.A.. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000; 30: 433–9.
- 15 Edson R.S., Terrell C.L.. The aminoglycosides. Mayo Clin Proc 1999; 74(5): 519–28.
- 16 Lacy M.K., Nicolau D.P., Nightingale C.H., et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23–7.
- 17 Levison M.E.. Pharmacodynamics of antibacterial drugs. Infect Dis Clin North Am 2000; 14(2): 281–91.
- 18 Moore R.D., Smith C.R., Lietman P.S.. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149(3): 443–8.
- 19 Moore R.D., Smith C.R., Lietman P.S.. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657–62.
- 20 Noonce P., Parsons T.M.C., Pattison J.R., et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; 1: 477–81.
- 21 Moore R.D., Lietman P.S., Smith C.R.. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155(1): 93–9.
- 22 Craig W.A.. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–12.
- 23 Daikos G.L., Jackson G.G., Lolans V.T., et al. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162: 414–20.
- 24 Daikos G.L., Lolans V.T., Jackson G.G.. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117–23.
- 25 Jackson G.G., Lolans V.T., Daikos G.L.. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: 408–13.
- 26 MacArthur R.F., Lolans V.T., Zar F.A., et al. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984; 150: 778–9.
- 27 Taketomo C.K., Hodding J.H., Kraus D.M.. Pediatric dosage handbook, 8th ed. Hudson, OH: Lexi-Comp, 2001.
- 28 MacKenzie F.M., Gould I.M.. The postantibiotic effect. J Antimicrob Chemother 1993; 32: 519–37.
- 29 Vogelman B.S., Craig W.A.. Postantibiotic effects. J Antimicrob Chemother 1985; 15(suppl A): 37–46.
- 30 Fantin B., Ebert S., Leggett J., et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1990; 27: 829–36.
- 31 Vogelman B., Gudmundsson S., Turnidge J.. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157(2): 287–98.
- 32 Van der Auwera P., Klastersky J.. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother 1987; 31(7): 1061–8.
- 33 Mingeot-Leclercq M.P., Tulkens P.. Aminoglycosides:nephrotoxicity. Antimicrob Agents Chemother 1999; 43(5): 1003–12.
- 34 Verpooten G.A., Giuliano R.A., Verbist L., et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45(1): 22–7.
- 35 Giuliano R.A., Verpooten G.A., Verbist L.. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470–5.
- 36 De Broe M.E., Verbist L., Verpooten G.A.. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27(suppl C): 41–7.
- 37 Bertino J.S., Booker L.A., Franck P.A., et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–9.
- 38 Rybak M.J., Abate B.J., Kang L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43(7): 1549–55.
- 39 Murry K.R., McKinnon P.S., Mitrzyk B., et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1999; 19(11): 1252–60.
- 40 Black F.O., Pesznecker S.C.. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 26(5): 713–36.
- 41 Matz G.J.. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993; 26(5): 705–12.
- 42 Govaerts P.J., Claes J., Van De Heyning P.H., et al. Amino-glycoside-induced ototoxicity. Toxicol Lett 1990; 52(3): 227–51.
- 43 Gatell J.M., Ferran F., Araujo V., et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987; 31: 1383–7.
- 44 Carapetis J.R., Jaquiery A.L., Buttery J.P., et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001; 20: 240–6.
- 45 Elhanan K., Siplovich L., Raz R.. Gentamicin once-daily versus thrice daily in children. J Antimicrob Chemother 1995; 35: 327–32.
- 46 Krivoy N., Postovsky S., Elhasid R., et al. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients. Infection 1998; 26: 396–8.
- 47 Postovsky S., Ben Arush M.W., Kassis E., et al. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997; 14: 547–54.
- 48 Vic P., Ategbo S., Turck D., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998; 78: 536–9.
- 49 Tomlinson R.J., Rohghe M., Goodbourne C., et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child 1999; 80: 125–31.
- 50 Bouffet E., Fuhrmann C., Frappaz D., et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70: 484–7.
- 51 Trujillo H., Robledo J., Robledo C., et al. Single daily dose amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991; 27(suppl C): 141–7.
- 52 Kafetzis D.A., Sianidou L., Vlachos E., et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991; 27(suppl C): 105–12.
- 53 Viscoli C., Dudley M., Ferrea G., et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27(suppl C): 113–20.
- 54 Bass K.D., Larkin S.E., Paap C., et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998; 33: 1104–7.
- 55 Bragonier R., Brown N.M.. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998; 42: 103–6.
- 56 Shankar S.M., Jew R.K., Bickert B.M., et al. Pharmacokinetics of single daily dose gentamicin in children with cancer. J Pediatr Hematol Oncol 1999; 21(4): 284–8.
- 57 Hitt C.M., Klepser M.E., Nightingale C.H., et al. Pharmaco-economic impact of once-daily aminoglycoside administration. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 1997; 17(4): 810–14.
